注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
糖基生医股份有限公司主要从事于糖分子相关技术的新药开发。该公司拥有的平台技术与产品开发依其专利特性可分为八大类,包括:均相化抗体药物、癌症与免疫相关疾病之单株抗体药物、糖类相关疫苗与药物、抗流感药物、糖精片开发与应用、糖探针开发与应用、糖分子合成鉴定及应用开发、创新开发计划衍生专利。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Chinh-Yi Wu | - | 2022 | GM & Board Member |
Ming-Hsing Tsai | 66 | 2022 | Director |
Chao-Long Chen | - | - | Chairman |
Shaw T. Chen | - | - | Member of Scientific Advisory Board |
Chi-Huey Wong | - | - | Chairman of Scientific Advisory Board |
Hsieng S. Lu | - | - | Member of Scientific Advisory Board |
Shuan-Ta Liu | - | 2019 | Independent Director |
Kuo-I Lin | - | 2021 | Member of Scientific Advisory Board |
Che Alex Ma | - | - | Member of Scientific Advisory Board |
Pan-Chyr Yang | - | - | Member of Scientific Advisory Board |
Chung-Yi Wu | - | 2022 | President, CEO, GM & Director |
Yun-Ching Yeh | - | 2022 | Board Member |
Victor Ma | - | 2022 | Board Member |
Mei-Shang Ho | - | 2021 | Member of Scientific Advisory Board |
Hong-Nerng Ho | - | - | Independent Director |
Chung-Liang Chien | - | - | Independent Director |
Shun-Ling Chen | - | 2022 | Board Member |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核